Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318265 · ClinicalTrials.gov registry record · Phase 1
Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
A Phase 1 study of Pharmacokinetics, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01318265 is a Phase 1 study of Pharmacokinetics that has completed, run by Bayer. The registered enrollment target is 24 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01318265, a Phase 1 study of Pharmacokinetics, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of BAY73-4506 in healthy male volunteers.
Conditions Studied
Interventions
- DRUG Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Study Locations (1)
Massachusetts
- - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01318265
The ClinicalTrials.gov registry entry for NCT01318265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (61% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole is the first listed.
NCT01318265 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01318265 about?
NCT01318265 is a clinical study titled "Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics". The purpose of this study is to estimate the effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of BAY73-4506 in healthy male volunteers.
What is the current status of trial NCT01318265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-03. Estimated completion is 2011-07.
What conditions does trial NCT01318265 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT01318265?
The interventions under investigation include: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole (DRUG).
Who is sponsoring clinical trial NCT01318265?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01318265 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.